American Epilepsy Society
Login
Home
Home
/ Eisai FDA Approves BANZEL™ (rufinamide)
Eisai FDA Approves BANZEL™ (rufinamide)
New release - November 14, 2008 - Eisai FDA Approves BANZEL™ (rufinamide) as Adjunctive Treatment for Severe Epilepsy Disorder
Home
About AES
History
Board of Directors
Staff
Committees
Task Forces
Bylaws
Donations
Membership
Membership Directory
Join Online
Membership Renewal
Membership Information
Special Interest Groups
Member Award Program
Committee Listing
Professional Development
Archived AES Symposia
Epilepsy Edu. Program
Postgrad Training Directory
Educational Opportunities
Career Opportunities
Medical Edu. Evaluator
Meetings & Events
Calendar of Events
Annual Meeting
Abstract Search
Research
Resources in Epilepsy Res.
Research Awards
AES Sponsored Grant Program
EF Sponsored Grant Programs
Publications
AES News
AES Abstracts
Epilepsy Currents
Annual Reports
Epilepsia
Patients
Find A Doctor
Post Traumatic Epilepsy
Epilepsy Facts & Figures
Practice
Rx Drug Assist. Programs
AED Guidelines
AED Info
AAN Practice Guideline
News
Practice Tools
Position Statements
Press Room
Annual Reports
Experts & Spokespersons
Fact Sheets and Positions
Leadership Biographies
Annual Meeting
Press Release Archive
Site Map
